A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p

摘要

We report a 77-year-old male patient with chronic lympho-cytic leukaemia (CLL), requiring the sixth line of treatment due to relapse with progressive lymphadenopathy, worsening thrombocytopenia and pronounced night sweats. First diagnosis was established 8 years earlier in 2004 with advanced stage disease (Binet C) and a high-risk profile consisting in high CD38 and ZAP70 expression. Initial fluorescence in situ hybridization showed deletion 13q in 65% of CLL cells without other chromosomal aberrations. Previous CLL-specific therapies are summarised in Table 1. When disease progressed again in August 2010, we opted for monotherapy with the fully humanized anti-CD20 antibody ofatumumab with a starting doses of 300 mg, followed by 2000 mg for 8 weekly infusions and subsequent 4 monthly infusions (1, 2).